Neurogene Inc.
NGNE
$29.82
-$1.45-4.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 22.57% | 19.01% | |||
| Gross Profit | -22.57% | -19.01% | |||
| SG&A Expenses | 19.00% | 5.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.67% | 15.17% | |||
| Operating Income | -21.67% | -15.17% | |||
| Income Before Tax | -25.06% | -18.05% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -25.06% | -18.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -25.06% | -18.05% | |||
| EBIT | -21.67% | -15.17% | |||
| EBITDA | -22.06% | -15.64% | |||
| EPS Basic | -23.81% | -13.16% | |||
| Normalized Basic EPS | -24.42% | -12.63% | |||
| EPS Diluted | -23.81% | -13.16% | |||
| Normalized Diluted EPS | -24.42% | -12.63% | |||
| Average Basic Shares Outstanding | 1.01% | 4.32% | |||
| Average Diluted Shares Outstanding | 1.01% | 4.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||